NextCure, Inc. has announced that the first patient has been dosed in its Phase 1 study of LNCB74, a drug being developed as a therapy for multiple types of cancer. The drug in question is a B7-H4-targeting antibody-drug conjugate (ADC). This information was released in a press release by the company.
Proper names in the text: - NextCure, Inc. - LNCB74 - Steven P. Cobourn